MX342104B - Derivados de cicloalquenil arilo para inhibidor de cetp. - Google Patents
Derivados de cicloalquenil arilo para inhibidor de cetp.Info
- Publication number
- MX342104B MX342104B MX2013011855A MX2013011855A MX342104B MX 342104 B MX342104 B MX 342104B MX 2013011855 A MX2013011855 A MX 2013011855A MX 2013011855 A MX2013011855 A MX 2013011855A MX 342104 B MX342104 B MX 342104B
- Authority
- MX
- Mexico
- Prior art keywords
- aryl derivatives
- cetp inhibitor
- cycloalkenyl aryl
- derivatives
- cholesterol
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 abstract 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con derivados de cicloalquenil arilo, isómeros de los mismos, sales farmacéuticamente aceptables de los mismos, hidratos de los mismos, o solvatos de los mismos; un método para preparar los derivados; y composiciones farmacéuticas que contienen los mismos. Los compuestos de la presente invención muestran el efecto de la inhibición de la actividad de CETP. Esto significa que los compuestos pueden incrementar el HDL-colesterol y hacer disminuir el LDL-colesterol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110033943 | 2011-04-12 | ||
| PCT/KR2012/002739 WO2012141487A2 (en) | 2011-04-12 | 2012-04-12 | Cycloalkenyl aryl derivatives for cetp inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011855A MX2013011855A (es) | 2013-11-01 |
| MX342104B true MX342104B (es) | 2016-09-13 |
Family
ID=47009830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011855A MX342104B (es) | 2011-04-12 | 2012-04-12 | Derivados de cicloalquenil arilo para inhibidor de cetp. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9371294B2 (es) |
| EP (1) | EP2697207B1 (es) |
| JP (1) | JP5820056B2 (es) |
| KR (1) | KR101442644B1 (es) |
| CN (1) | CN103502226B (es) |
| AU (1) | AU2012243583B2 (es) |
| BR (1) | BR112013026280A2 (es) |
| CA (1) | CA2829676C (es) |
| DK (1) | DK2697207T3 (es) |
| ES (1) | ES2617221T3 (es) |
| HR (1) | HRP20170422T1 (es) |
| HU (1) | HUE032075T2 (es) |
| MX (1) | MX342104B (es) |
| PH (1) | PH12013501829A1 (es) |
| PL (1) | PL2697207T3 (es) |
| PT (1) | PT2697207T (es) |
| RU (1) | RU2597266C2 (es) |
| WO (1) | WO2012141487A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033790T2 (en) * | 2013-01-31 | 2017-12-28 | Chong Kun Dang Pharmaceutical Corp | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors |
| WO2016154873A1 (zh) * | 2015-03-31 | 2016-10-06 | 华为技术有限公司 | 一种终端设备和拍照的方法 |
| CN107304174B (zh) * | 2016-04-21 | 2019-05-10 | 沈阳药科大学 | N,n-双取代环烯基甲胺类衍生物及其制备方法和应用 |
| IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| JP7526673B2 (ja) | 2018-02-20 | 2024-08-01 | インサイト・コーポレイション | がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN110759860B (zh) * | 2018-07-27 | 2022-10-14 | 江苏瑞科医药科技有限公司 | 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929094A (en) | 1996-10-25 | 1999-07-27 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| ES2256461T3 (es) | 2001-04-30 | 2006-07-16 | Pfizer Products Inc. | Compuestos utiles como intermediarios de derivados de 4-aminoquinolina. |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| WO2007079186A2 (en) * | 2005-12-30 | 2007-07-12 | Merck & Co., Inc. | 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors |
| EP1973546B1 (en) * | 2005-12-30 | 2012-06-13 | Merck Sharp & Dohme Corp. | Cholesteryl ester transfer protein inhibitors |
| US7910592B2 (en) | 2005-12-30 | 2011-03-22 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| CA2681628C (en) * | 2007-03-16 | 2016-10-18 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039474A1 (en) * | 2008-10-01 | 2010-04-08 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone cetp inhibitors |
-
2012
- 2012-04-12 HR HRP20170422TT patent/HRP20170422T1/hr unknown
- 2012-04-12 EP EP12770951.7A patent/EP2697207B1/en active Active
- 2012-04-12 JP JP2014505076A patent/JP5820056B2/ja not_active Expired - Fee Related
- 2012-04-12 CN CN201280017898.2A patent/CN103502226B/zh not_active Expired - Fee Related
- 2012-04-12 AU AU2012243583A patent/AU2012243583B2/en not_active Ceased
- 2012-04-12 WO PCT/KR2012/002739 patent/WO2012141487A2/en not_active Ceased
- 2012-04-12 DK DK12770951.7T patent/DK2697207T3/en active
- 2012-04-12 MX MX2013011855A patent/MX342104B/es active IP Right Grant
- 2012-04-12 PL PL12770951T patent/PL2697207T3/pl unknown
- 2012-04-12 HU HUE12770951A patent/HUE032075T2/en unknown
- 2012-04-12 US US14/110,271 patent/US9371294B2/en not_active Expired - Fee Related
- 2012-04-12 BR BR112013026280A patent/BR112013026280A2/pt not_active IP Right Cessation
- 2012-04-12 RU RU2013145418/04A patent/RU2597266C2/ru active
- 2012-04-12 KR KR20120037886A patent/KR101442644B1/ko not_active Expired - Fee Related
- 2012-04-12 PH PH1/2013/501829A patent/PH12013501829A1/en unknown
- 2012-04-12 CA CA2829676A patent/CA2829676C/en active Active
- 2012-04-12 PT PT127709517T patent/PT2697207T/pt unknown
- 2012-04-12 ES ES12770951.7T patent/ES2617221T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103502226B (zh) | 2015-08-19 |
| EP2697207A2 (en) | 2014-02-19 |
| US20150119376A2 (en) | 2015-04-30 |
| JP2014510786A (ja) | 2014-05-01 |
| HUE032075T2 (en) | 2017-08-28 |
| KR20120116362A (ko) | 2012-10-22 |
| EP2697207A4 (en) | 2014-11-19 |
| WO2012141487A2 (en) | 2012-10-18 |
| DK2697207T3 (en) | 2017-03-27 |
| RU2013145418A (ru) | 2015-05-20 |
| JP5820056B2 (ja) | 2015-11-24 |
| RU2597266C2 (ru) | 2016-09-10 |
| AU2012243583B2 (en) | 2015-10-22 |
| CA2829676A1 (en) | 2012-10-18 |
| ES2617221T3 (es) | 2017-06-15 |
| WO2012141487A3 (en) | 2013-01-10 |
| EP2697207B1 (en) | 2016-12-14 |
| HRP20170422T1 (hr) | 2017-06-16 |
| US20140031335A1 (en) | 2014-01-30 |
| CN103502226A (zh) | 2014-01-08 |
| MX2013011855A (es) | 2013-11-01 |
| NZ615071A (en) | 2015-05-29 |
| PH12013501829A1 (en) | 2015-10-23 |
| BR112013026280A2 (pt) | 2024-04-30 |
| CA2829676C (en) | 2017-08-22 |
| PL2697207T3 (pl) | 2017-08-31 |
| AU2012243583A1 (en) | 2013-10-03 |
| KR101442644B1 (ko) | 2014-09-19 |
| US9371294B2 (en) | 2016-06-21 |
| PT2697207T (pt) | 2017-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501829A1 (en) | Cycloalkenyl aryl derivatives for cetp inhibitor | |
| PH12019500163A1 (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| MX2016017147A (es) | Compuestos de indazole substituidos como inhibidores de irak4. | |
| NZ723772A (en) | Neprilysin inhibitors | |
| MD20180040A2 (ro) | Inhibitori ai virusului hepatic C | |
| MY172924A (en) | Neprilysin inhibitors | |
| MD20160118A2 (ro) | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 | |
| MY184303A (en) | Notch pathway signaling inhibitor compound | |
| MY176803A (en) | Polymorph of syk inhibitors | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| MX353190B (es) | Derivados de isoquinolina y naftiridina. | |
| MX362879B (es) | Usos novedosos. | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| PH12014502492A1 (en) | Pyrazole compounds as sglt1 inhibitors | |
| MX2013011333A (es) | Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. | |
| PH12015501223B1 (en) | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
| PH12013501830A1 (en) | Peptide deformylase inhibitors | |
| IN2013MU03670A (es) | ||
| MX2015013551A (es) | Sales de amina de pitavastatina farmaceuticamente aceptables. | |
| TN2013000515A1 (en) | Notch pathway signaling inhibitor compound | |
| TN2014000307A1 (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors | |
| TN2013000035A1 (en) | Highly crystalline valsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: CHONG KUN DANG PHARMACEUTICAL CORP. |
|
| HC | Change of company name or juridical status |
Owner name: PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AME Owner name: HANMI SCIENCE CO., LTD.* |
|
| FG | Grant or registration |